Caterina Peraldo‐Neia

965 total citations
32 papers, 667 citations indexed

About

Caterina Peraldo‐Neia is a scholar working on Surgery, Oncology and Cancer Research. According to data from OpenAlex, Caterina Peraldo‐Neia has authored 32 papers receiving a total of 667 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Surgery, 19 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Caterina Peraldo‐Neia's work include Cholangiocarcinoma and Gallbladder Cancer Studies (19 papers), Cancer Mechanisms and Therapy (8 papers) and MicroRNA in disease regulation (7 papers). Caterina Peraldo‐Neia is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (19 papers), Cancer Mechanisms and Therapy (8 papers) and MicroRNA in disease regulation (7 papers). Caterina Peraldo‐Neia collaborates with scholars based in Italy, Switzerland and Belgium. Caterina Peraldo‐Neia's co-authors include Massimo Aglietta, Giuliana Cavalloni, Giovanna Chiorino, Francesco Leone, Giorgia Migliardi, Ymera Pignochino, Ivana Sarotto, Chiara Varamo, Laura Casorzo and Filippo Montemurro and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Caterina Peraldo‐Neia

32 papers receiving 663 citations

Peers

Caterina Peraldo‐Neia
Comparison fields: 5 of 66
  • Oncology 347
  • Surgery 324
  • Molecular Biology 209
  • Cancer Research 187
  • Pulmonary and Respiratory Medicine 166
Replace Jianbo Zhang with:
Jianbo Zhang China
Soo Hee Kim South Korea
Fangchao Zheng China
A. Reinacher-Schick Germany
Maria D. Begnami Brazil
Adam G. Mace United States
F. De Vita Italy
Chongkai Wang United States
Jiemin Zhao China
Xinmin Zhao China
Jianbo Zhang China View profile →
Citations per field, relative to Caterina Peraldo‐Neia
Caterina Peraldo‐Neia · 1×
Citations per year, relative to Caterina Peraldo‐Neia
Caterina Peraldo‐Neia · 1×

Countries citing papers authored by Caterina Peraldo‐Neia

Since Specialization
Citations

This map shows the geographic impact of Caterina Peraldo‐Neia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caterina Peraldo‐Neia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caterina Peraldo‐Neia more than expected).

Fields of papers citing papers by Caterina Peraldo‐Neia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caterina Peraldo‐Neia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caterina Peraldo‐Neia. The network helps show where Caterina Peraldo‐Neia may publish in the future.

Co-authorship network of co-authors of Caterina Peraldo‐Neia

This figure shows the co-authorship network connecting the top 25 collaborators of Caterina Peraldo‐Neia. A scholar is included among the top collaborators of Caterina Peraldo‐Neia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caterina Peraldo‐Neia. Caterina Peraldo‐Neia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
2025 ·Cancers ·Annamaria Massa, (unknown), Caterina Peraldo‐Neia, Chiara Varamo, Marco Basiricò, Chiara Raggi, Paola Bernabei, Jessica Erriquez, Francesco Leone, Massimo Aglietta, Giuliana Cavalloni, Serena Marchiò
1
2
Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer
2024 ·European Radiology ·Simone Mazzetti, Arianna Defeudis, (unknown), Giovanna Chiorino, Stefano De Luca, Riccardo Faletti, Marco Gatti, Paolo Gontero, Matteo Manfredi, Maurizia Mello‐Grand, Caterina Peraldo‐Neia, Andrea Zitella, F. Porpiglia, Daniele Regge, Valentina Giannini
2
3
Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
2022 ·Frontiers in Oncology ·Annamaria Massa, Caterina Peraldo‐Neia, (unknown), Chiara Varamo, Marco Basiricò, Chiara Raggi, Paola Bernabei, Jessica Erriquez, Ivana Sarotto, Francesco Leone, Serena Marchiò, Giuliana Cavalloni, Massimo Aglietta
4
4
Identification of Novel Circulating microRNAs in Advanced Heart Failure by Next-Generation Sequencing
2021 ·ESC Heart Failure ·Alessandro Galluzzo, Simona Gallo, Barbara Pardini, Giovanni Birolo, Piero Fariselli, (unknown), Annapia Vitacolonna, Caterina Peraldo‐Neia, (unknown), Alessandra Volpe, (unknown), Stefano Pidello, Alessandro Bonzano, Giuseppe Matullo, Carla Giustetto, Serena Bergerone, Tiziana Crepaldi
32
5
Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients
2021 ·BMC Cancer ·Giuliana Cavalloni, Caterina Peraldo‐Neia, Annamaria Massa, Carlo M. Bergamini, Alessandro Trentini, Gaetano De Rosa, Lorenzo Daniele, Fabiola Ciccosanti, Carlo Cervellati, Francesco Leone, Massimo Aglietta
11
6
A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient
2021 ·Cancers ·Caterina Peraldo‐Neia, Annamaria Massa, (unknown), Marco Basiricò, Chiara Raggi, Paola Bernabei, Paola Ostano, Laura Casorzo, (unknown), Francesco Leone, Giuliana Cavalloni, Massimo Aglietta
10
7
Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA
2021 ·Frontiers in Oncology ·Maurizia Mello‐Grand, Antonino Bruno, Lidia Sacchetto, Simone Cristoni, Ilaria Gregnanin, (unknown), Andrea Zitella, Paolo Gontero, Caterina Peraldo‐Neia, Riccardo Ricotta, Douglas M. Noonan, Adriana Albini, Giovanna Chiorino
8
8
448P Predictive factor of cardiotoxicity in fluoropyrimidine-treated colorectal cancer patients: Interim analysis of the prospective observational CHECKPOINT trial
2020 ·Annals of Oncology ·(unknown), Pasquale Lombardi, (unknown), (unknown), (unknown), (unknown), Roberto Filippi, R Ferraris, Alessandro Bonzano, Giuliana Cavalloni, Caterina Peraldo‐Neia, Massimo Aglietta, Francesco Leone, Elisabetta Fenocchio
1
9
Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: Preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)
2019 ·Annals of Oncology ·Pasquale Lombardi, (unknown), Ilaria Depetris, Alessandro Bonzano, Roberto Filippi, Elisabetta Fenocchio, (unknown), (unknown), R Ferraris, Celeste Cagnazzo, Caterina Peraldo‐Neia, Marco Basiricò, Giuliana Cavalloni, Massimo Aglietta, Francesco Leone
1
10
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma
2018 ·BMC Genomics ·Caterina Peraldo‐Neia, Paola Ostano, Giuliana Cavalloni, Ymera Pignochino, Dario Sangiolo, Loris De Cecco, Edoardo Marchesi, Dario Ribero, Aldo Scarpa, Agostino Maria De Rose, Antonio Giuliani, Fulvio Calise, Chiara Raggi, Pietro Invernizzi, Massimo Aglietta, Giovanna Chiorino, Francesco Leone
12
11
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR
2018 ·PLoS ONE ·Caterina Peraldo‐Neia, Giuliana Cavalloni, Elisabetta Fenocchio, Celeste Cagnazzo, Loretta Gammaitoni, Stefano Cereda, Guglielmo Nasti, Maria Antonietta Satolli, Giuseppe Aprile, Michele Reni, Antonio Avallone, Rosella Spadi, Tiziana Venesio, Vittoria Martin, Claudio Doglioni, Milo Frattini, Massimo Aglietta, Francesco Leone
13
12
Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line
2016 ·Oncotarget ·Caterina Peraldo‐Neia, Giuliana Cavalloni, Giovanna Chiorino, Paola Ostano, Massimo Aglietta, Francesco Leone
12
13
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation
2016 ·BMC Cancer ·Giuliana Cavalloni, Caterina Peraldo‐Neia, Francesco Sassi, Giovanna Chiorino, Ivana Sarotto, Massimo Aglietta, Francesco Leone
31
14
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
2014 ·BMC Cancer ·Caterina Peraldo‐Neia, Giuliana Cavalloni, Marco Soster, Loretta Gammaitoni, Serena Marchiò, Francesco Sassi, Livio Trusolino, Andrea Bertotti, Enzo Médico, Lorenzo Capussotti, Massimo Aglietta, Francesco Leone
7
15
Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer
2013 ·Molecular Oncology ·Filippo Montemurro, Aleix Prat, Valentina Rossi, Giorgio Valabrega, Jeff Sperinde, Caterina Peraldo‐Neia, Michela Donadio, Patricia Galván, Anna Sapino, Massimo Aglietta, José Baselga, Maurizio Scaltriti
35
16
Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2012 ·Molecular Cancer Therapeutics ·Giuliana Cavalloni, Caterina Peraldo‐Neia, Ivana Sarotto, Loretta Gammaitoni, Giorgia Migliardi, Marco Soster, Serena Marchiò, Massimo Aglietta, Francesco Leone
13
17
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
2011 ·BMC Cancer ·Caterina Peraldo‐Neia, Giorgia Migliardi, Maurizia Mello‐Grand, Filippo Montemurro, (unknown), Ymera Pignochino, Giuliana Cavalloni, Bruno Torchio, (unknown), Giovanna Chiorino, Massimo Aglietta
81
18
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
2010 ·Breast Cancer Research and Treatment ·Giorgio Valabrega, (unknown), Giuliana Cavalloni, Gianluca Zaccarello, Annalisa Petrelli, Giorgia Migliardi, Andrea Milani, Caterina Peraldo‐Neia, Loretta Gammaitoni, Anna Sapino, Carla Pecchioni, Aldo Moggio, Silvia Giordano, Massimo Aglietta, Filippo Montemurro
35
19
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
2010 ·BMC Cancer ·Ymera Pignochino, Ivana Sarotto, Caterina Peraldo‐Neia, Junia Y. Penachioni, Giuliana Cavalloni, Giorgia Migliardi, Laura Casorzo, Giovanna Chiorino, Mauro Risio, Alberto Bardelli, Massimo Aglietta, Francesco Leone
143
20
Abstract A82: HHER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and become sensitive to the multitargeted kinase inhibitor sorafenib
2009 ·Molecular Cancer Therapeutics ·(unknown), Giorgio Valabrega, Giuliana Cavalloni, Gianluca Zaccarello, Annalisa Petrelli, Giorgia Migliardi, Andrea Milani, Caterina Peraldo‐Neia, Loretta Gammaitoni, Francesco Favero, Aldo Moggio, Silvia Giordano, Massimo Aglietta, Filippo Montemurro
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianbo Zhang Breakdown of academic impact, for papers by Soo Hee Kim Breakdown of academic impact, for papers by Fangchao Zheng Breakdown of academic impact, for papers by A. Reinacher-Schick Breakdown of academic impact, for papers by Maria D. Begnami Breakdown of academic impact, for papers by Adam G. Mace Breakdown of academic impact, for papers by F. De Vita Breakdown of academic impact, for papers by Chongkai Wang Breakdown of academic impact, for papers by Jiemin Zhao Breakdown of academic impact, for papers by Xinmin Zhao
Rankless by CCL
2026